Palatin gears up for obesity treatment trials in 2025

CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for obesity and related diseases. According to InvestingPro data, the company's stock has experienced significant volatility, declining nearly 80% over the past year. The biopharmaceutical company is preparing to report topline results from a Phase 2 clinical study of its MC4R agonist bremelanotide in combination with the dual agonist tirzepatide. This study, expected to conclude in the first quarter of 2025, aims to assess the safety and efficacy of the drug duo in reducing body weight.

Palatin's obesity programs are set to expand in the second half of 2025 with the initiation of multiple clinical trials involving a long-acting MC4R peptide and an MC4R selective oral small molecule compound. These trials will target general obesity, weight loss management, and specific rare neuroendocrine and genetic diseases, including hypothalamic obesity.

The company's approach leverages the melanocortin 4 receptor (MC4R), which has been validated as a key regulator of appetite and energy expenditure. Palatin's expertise in modulating the melanocortin receptor system positions it as a leader in the development of potential new treatments for obesity. However, InvestingPro analysis reveals the company is rapidly burning through cash, with negative EBITDA of $31.6 million in the last twelve months.

In addition to the obesity programs, Palatin is engaged in discussions for licensing, collaboration, and spinout deals for its dry eye disease, ulcerative colitis, and diabetic nephropathy programs, with multiple agreements anticipated throughout 2025.

Palatin's strategy involves advancing its product candidates through clinical development and then forming marketing collaborations to maximize their commercial potential. The company's updates are based on a press release statement and reflect its forward-looking plans for the year.

Investors and industry watchers will be closely monitoring the outcomes of Palatin's clinical studies and the potential impact of its MC4R agonists on the treatment landscape for obesity and related health conditions. With current financial metrics indicating challenges ahead, detailed analysis is crucial. InvestingPro subscribers can access 12 additional ProTips and comprehensive financial health scores to better evaluate Palatin's investment potential through the platform's detailed Pro Research Report.

In other recent news, Palatin Technologies has completed the enrollment phase of its Phase 2 clinical trial for PL8177, a melanocortin-1 receptor agonist being tested for ulcerative colitis. The company has also maintained its Buy rating from H.C. Wainwright, reflecting a positive outlook on its potential. A strategic shift has led Palatin to seek third-party partners for the development of PL8177, as it refocuses resources on its obesity program.

The company also faced a non-compliance notice from NYSE American LLC but has had its compliance plan accepted, allowing it to remain listed until 2025. Meanwhile, despite reporting no product sales for the fourth quarter of fiscal year 2024, Palatin managed to reduce operating expenses and completed several clinical trials. It also sold its product Vyleesi to Cosette Pharmaceuticals for up to $171 million.

On the clinical front, Palatin has advanced its drug development programs, completing a successful Phase III trial for PL9643 for dry eye disease and initiating a Phase II study for obesity treatment. These are among the recent developments in the company's operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.